With effect from February 29, 2024, the unit rightsin Nasdaq will be traded on the list for Equity rights. Trading will continue up until and including March 08, 2024. Instrument: Unit rights Short name: XBRANE UR Clearing: Bilateral settlement at Euroclear Sweden ISIN code: SE0021515103 Order book ID: 325544 Market Segment: OMX STO Eq.rights,Subs.Opt, Int. shares Tick Size: MiFID II tick size table With effect from February 29, 2024, the paid subscription units in Xbrane Biopharma AB will be traded on the list for Equity rights. Trading will continue up until further notice. Instrument: Paid subscription units Short name: XBRANE BTU Clearing: Bilateral settlement at Euroclear Sweden ISIN code: SE0021515111 Order book ID: 325545 Market Segment: OMX STO Eq.rights,Subs.Opt, Int. shares Tick Size: MiFID II tick size table For further information concerning this exchange notice please contact Issuer Surveillance, telephone +46 8 405 70 50, or iss@nasdaq.com Nasdaq Stockholm AB
Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Xbrane Biopharma AB (21/24)
© 2024 GlobeNewswire
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 26.03. | Nasdaq Stockholm AB: New equity right for trading, Xbrane Biopharma AB TO 1 | At the request of Xbrane Biopharma AB, Xbrane Biopharma equity rights will be
traded on First North Growth Market as from March 27, 2024.
Security name: Xbrane Biopharma AB TO 1
----------------------------------------
Short... ► Artikel lesen | |
| 19.03. | Nasdaq Stockholm AB: Delisting of paid subscription units in Xbrane Biopharma AB | The paid subscription units in Xbrane Biopharma AB will be delisted. Last
trading day for XBRANE BTUwill be on March 20, 2024.
Instrument: Paid subscription units
--------------------------------------
Short... ► Artikel lesen | |
| 28.02. | Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Xbrane Biopharma AB (21/24) | With effect from February 29, 2024, the unit rightsin Nasdaq will be traded on
the list for Equity rights. Trading will continue up until and including March
08, 2024.
Instrument: Unit rights ... ► Artikel lesen | |
| 28.02. | Nasdaq Stockholm AB: Xbrane Biopharma AB ges observationsstatus / Xbrane Biopharma AB receives observation status (20/24) | Den 26 februari 2024 offentliggjorde Xbrane Biopharma AB ("Bolaget") dess
bokslutskommuniké för 2023 med information om Bolagets finansiella ställning.
Den 27 februari 2024 offentliggjorde Bolaget... ► Artikel lesen | |
| 26.02. | Xbrane Biopharma AB: Xbrane Biopharma releases Year-end Report 2023 | Xbrane Biopharma AB's (publ.) ("Xbrane") Year-end Report 2023, is as of today, available on the Company's website, www.xbrane.com.
FINANCIAL OVERVIEWFOURTH QUARTER 2023*• Revenue amounted to SEK 66.9... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen.
Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen,
bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen
Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu
verstehen sein kann.
